Cevimeline
A cholinergic agonist that stimulates muscarinic M3 receptors in exocrine glands, increasing saliva and tear production. It is indicated for the treatment of dry mouth in patients with Sjögren's syndrome. Common side effects reflect its muscarinic stimulation and include sweating, nausea, and urinary frequency.
Molekularmasse
199,3200 g/mol
LogP
1,50
TPSA
37,80 Ų
Lipinski-Regel der Fünf
Bestanden
Wirkmechanismus
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CC1OC2(CS1)CN1CCC2CC1
InChI
InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3
Molecular Formula
C10H17NOS
HBD / HBA
- / 3
Rotierbare Bindungen
0
Schwere Atome
13
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A cholinergic agonist that stimulates muscarinic M3 receptors in exocrine glands, increasing saliva and tear production. It is indicated for the treatment of dry mouth in patients with Sjögren's syndrome. Common side effects reflect its muscarinic stimulation and include sweating, nausea, and urinary frequency.
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Yes, Cevimeline is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL168815. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 25137844. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cevimeline"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cevimeline/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cevimeline/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cevimeline/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cevimeline"></drugfyi-drug>